Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Q2 2026 Earnings Presentation
16 slides from Rockwell Medical's earnings presentation, Aug 13, 2026
Slide 1: Investor Presentation
Investor Presentation August 13, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, 2024, 2025 and 2026 guidance, fut
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance • Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide Business • Leading supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview • One of the largest s
Slide 4: Executive Management Team
Executive Management Team Mark Strobeck, PhD Jesse Neri Heather Hunter Tim Chole Megan Timmins President and CEO Chief Financial Officer Chief Operating Officer Chief Commercial Officer Chief Legal Officer ©2026 Rockwell Medical, Inc. 4 ©2026 Rockwell Medical, Inc.
Slide 5: Leading Manufacturer and Supplier of Hemodialysis Concentrates
Leading Manufacturer and Supplier of Hemodialysis Concentrates Hemodialysis is a Necessity for End Stage Kidney Disease Patients • Approximately 490,000 patients in the U.S. require in-center hemodialysis annually(a). • Each patient receives approximately three treatments per week, totaling approxim
Slide 6: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM
U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease $450M $560M 2024 2028 SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) 6 ©2026 R
Slide 7: Rockwell Currently Serves ~300 Customers throughout the U.S.
Rockwell Currently Serves ~300 Customers throughout the U.S. including Top Five Leading Dialysis Providers Dialysis Providers Hospital Systems Supplier Partners / Distributors 7 ©2026 Rockwell Medical, Inc.
Slide 8: Rockwell Distributes to 30+ Countries Worldwide
Rockwell Distributes to 30+ Countries Worldwide Current Geographic Footprint Current Expansion Opportunities 8 ©2026 Rockwell Medical, Inc.
Slide 9: Financials and Milestones
QROCKWELL Financials and Milestones
Slide 10: Second Quarter 2026 Financial Results
Second Quarter 2026 Financial Results Three Months Ended Six Months Ended June 30 June 30 (In Millions, Except Per Share Amounts) 2026 2025 2026 2025 Net Sales $ 17.8 $ 16.1 $ 35.1 $ 35.0 Gross Profit $ 3.2 $ 2.5 $ 6.1 $ 5.5 Gross Margin 18% 16% 17% $ 16% Operating Income (Loss) $ (1.1) $ (1.3) $ (2
Slide 11: On Track to Achieve Record Gross Margin in 2026
On Track to Achieve Record Gross Margin in 2026 $10.0 25% 18% - 22% $5.0 $2.0 20% $0.4 $0.0 $(3.9) 17% 17% 15% -$10.0 10% $(13.8) 10% 6% 5% -$20.0 0% $(28.4) -$30.0 -4% -5% 2021 2022 2023 2024 2025 2026 Guidance Adjusted EBITDA Gross Margin 11 ©2026 Rockwell Medical, Inc.
Slide 12: 3-Year Corporate Strategy (2026-2029)
3-Year Corporate Strategy (2026-2029) Maintain profitable business serving dialysis centers in worldwide • Reliable supply • Consistent quality • Strong customer service • Sustainable margin performance • Shareholder return Build a broader portfolio of renal care products • Integrate into our existi
Slide 13: Long-Term Financial Framework Through 2029
Long-Term Financial Framework Through 2029 Net Sales Profitability Gross Margin $100+ Million $5 Million to $10 million +30% Rockwell Medical believes the Company has a pathway to meaningfully grow its business and generate annual net sales of more than $100 million. Ongoing portfolio diversificatio
Slide 14: Why Invest in Rockwell Medical (Nasdaq: RMTI)?
Why Invest in Rockwell Medical (Nasdaq: RMTI)? ▪ Large, Recurring Market Opportunity ▪ Profitable, Revenue-Generating Business ▪ Projects to be Cash Flow Positive from Operations in 2026 and beyond ▪ Pursuing Investments in High-Growth Renal Care Opportunities ▪ No Additional Fundraising Required to
Slide 15: www.rockwellmed.com
www.rockwellmed.com IR@rockwellmed.com
Slide 16: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat